Sign In
Buy THC
$178.75
+6.18 (+3.58%)
At Close: Jun 22, 2026
Tenet Healthcare Corporation (THC) Q4 2024 Earnings Call Transcript
03:26pm, Wednesday, 12'th Feb 2025
Tenet Healthcare Corporation (NYSE:THC ) Q4 2024 Earnings Conference Call February 12, 2025 10:00 AM ET Company Participants Will McDowell - Vice President of Investor Relations Saumya Sutaria - Chair
Compared to Estimates, Tenet (THC) Q4 Earnings: A Look at Key Metrics
10:36am, Wednesday, 12'th Feb 2025
The headline numbers for Tenet (THC) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimate
Tenet Healthcare (THC) Surpasses Q4 Earnings Estimates
08:56am, Wednesday, 12'th Feb 2025
Tenet Healthcare (THC) came out with quarterly earnings of $3.44 per share, beating the Zacks Consensus Estimate of $2.93 per share. This compares to earnings of $2.68 per share a year ago.
Tenet Reports Strong Fourth Quarter and FY 2024 Results; Provides 2025 Financial Outlook
06:45am, Wednesday, 12'th Feb 2025
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended December 31, 2024. "2024 was an outstanding year for Tenet characterized by
Can Tenet Healthcare Navigate Through Lower Revenues in Q4?
12:31pm, Tuesday, 11'th Feb 2025
THC's fourth-quarter results are likely to reflect growing patient admissions, utilization and patient days.
Wall Street Analysts See Tenet (THC) as a Buy: Should You Invest?
10:31am, Friday, 07'th Feb 2025
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Countdown to Tenet (THC) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
10:21am, Friday, 07'th Feb 2025
Get a deeper insight into the potential performance of Tenet (THC) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some
Tenet Healthcare (THC) Stock Drops Despite Market Gains: Important Facts to Note
07:05pm, Tuesday, 04'th Feb 2025
Tenet Healthcare (THC) closed the most recent trading day at $143.71, moving -0.64% from the previous trading session.
Thriving in Healthcare: 5 Hospital Stocks to Keep on Your Radar
10:30am, Monday, 03'rd Feb 2025
The Zacks Medical-Hospital industry is likely to benefit from improving financial, operating and staffing stability. Companies like HCA, THC, UHS, ACHC and CYH are well-positioned to gain from these t
Tenet Healthcare Corporation (THC) is Attracting Investor Attention: Here is What You Should Know
10:00am, Thursday, 30'th Jan 2025
Tenet (THC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Tenet Healthcare (THC) Advances But Underperforms Market: Key Facts
07:06pm, Tuesday, 28'th Jan 2025
The latest trading day saw Tenet Healthcare (THC) settling at $139.67, representing a +0.56% change from its previous close.
Here's Why Tenet Healthcare (THC) is a Strong Growth Stock
10:45am, Monday, 27'th Jan 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Tenet Healthcare (THC) is a Top Value Stock for the Long-Term
10:41am, Thursday, 23'rd Jan 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tenet Healthcare (THC) Stock Dips While Market Gains: Key Facts
07:21pm, Wednesday, 22'nd Jan 2025
Tenet Healthcare (THC) concluded the recent trading session at $134.42, signifying a -0.01% move from its prior day's close.
Should You Invest in Tenet (THC) Based on Bullish Wall Street Views?
10:31am, Wednesday, 22'nd Jan 2025
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
